Search research articles
Contact Us
Filters
Showing results (141-150 of 263) with videos related to
Page
of 27
Sort By:
British Journal of Clinical Pharmacology
|
December 1, 1996
A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: association with diminished debrisoquine hydroxylase activity
C Masimirembwa, I Persson, L Bertilsson, et al.
British Journal of Clinical Pharmacology
|
February 12, 1998
The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine
B Eiermann, G Engel, I Johansson, et al.
Clinical Pharmacology and Therapeutics
|
August 1, 1981
E- and Z-10-hydroxylation of nortriptyline: relationship to polymorphic debrisoquine hydroxylation
B Mellström, L Bertilsson, J Säwe, et al.
British Journal of Clinical Pharmacology
|
April 1, 1988
Enantioselectivity of 4-hydroxylation in extensive and poor metabolizers of debrisoquine
M Eichelbaum, L Bertilsson, A Küpfer, et al.
Clinical Pharmacology and Therapeutics
|
October 1, 1983
Amitriptyline metabolism: relationship to polymorphic debrisoquine hydroxylation
B Mellström, L Bertilsson, Y C Lou, et al.
Pharmacogenetics
|
December 1, 1996
S-mephenytoin hydroxylation phenotype and CYP2C19 genotype among Ethiopians
I Persson, E Aklillu, F Rodrigues, et al.
Pharmacogenetics
|
December 1, 1995
Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype
M Chang, M L Dahl, G Tybring, et al.
Lancet (London, England)
|
May 16, 1981
Hydroxylation of debrisoquine in patients with lacticacidosis after phenformin
B E Wiholm, G Alvan, L Bertilsson, et al.
Alimentary Pharmacology & Therapeutics
|
November 9, 2000
Omeprazole and CYP2C19 polymorphism: effects of long-term treatment on gastrin, pepsinogen I, and chromogranin A in patients with acid related disorders
M Sagar, L Bertilsson, M Stridsberg, et al.
Archives of General Psychiatry
|
November 1, 1980
Clomipramine treatment of obsessive-compulsive disorder. II. Biochemical aspects
P Thorén, M Asberg, L Bertilsson, et al.
Page
of 27
Search research articles
Search
Showing results (141-150 of 263) with videos related to
Sort By:
Page
of 27
British Journal of Clinical Pharmacology
|
December 1, 1996
A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: association with diminished debrisoquine hydroxylase activity
C Masimirembwa, I Persson, L Bertilsson, et al.
British Journal of Clinical Pharmacology
|
February 12, 1998
The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine
B Eiermann, G Engel, I Johansson, et al.
Clinical Pharmacology and Therapeutics
|
August 1, 1981
E- and Z-10-hydroxylation of nortriptyline: relationship to polymorphic debrisoquine hydroxylation
B Mellström, L Bertilsson, J Säwe, et al.
British Journal of Clinical Pharmacology
|
April 1, 1988
Enantioselectivity of 4-hydroxylation in extensive and poor metabolizers of debrisoquine
M Eichelbaum, L Bertilsson, A Küpfer, et al.
Clinical Pharmacology and Therapeutics
|
October 1, 1983
Amitriptyline metabolism: relationship to polymorphic debrisoquine hydroxylation
B Mellström, L Bertilsson, Y C Lou, et al.
Pharmacogenetics
|
December 1, 1996
S-mephenytoin hydroxylation phenotype and CYP2C19 genotype among Ethiopians
I Persson, E Aklillu, F Rodrigues, et al.
Pharmacogenetics
|
December 1, 1995
Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype
M Chang, M L Dahl, G Tybring, et al.
Lancet (London, England)
|
May 16, 1981
Hydroxylation of debrisoquine in patients with lacticacidosis after phenformin
B E Wiholm, G Alvan, L Bertilsson, et al.
Alimentary Pharmacology & Therapeutics
|
November 9, 2000
Omeprazole and CYP2C19 polymorphism: effects of long-term treatment on gastrin, pepsinogen I, and chromogranin A in patients with acid related disorders
M Sagar, L Bertilsson, M Stridsberg, et al.
Archives of General Psychiatry
|
November 1, 1980
Clomipramine treatment of obsessive-compulsive disorder. II. Biochemical aspects
P Thorén, M Asberg, L Bertilsson, et al.
Page
of 27